Impact BioMedical (IBO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IBO SEC filings page.
Impact BioMedical, Inc. (IBO) reported $32K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The numbers describe a development-stage business: FY2025 revenue was $32K against an $11.8M net loss, while operations used $1.89M of cash.
From FY2022 to FY2025, revenue fell-36.0% while SG&A rose168.6% ; the cost structure shifted toward overhead even as the commercial base contracted.
The scale remains development-oriented: R&D was
The earnings-to-cash gap was wide: FY2025 net loss was
Financial Health Signals
We do not publish a peer-relative financial health score for Impact BioMedical, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Impact BioMedical, Inc. scores 6.27, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $34.3M against total liabilities of $1.9M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Impact BioMedical, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Impact BioMedical, Inc. reported a net loss of $11.8M while operations used $1.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Impact BioMedical, Inc. reported an operating loss of $4.3M against $793K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Impact BioMedical, Inc. generated $3K in revenue in Q2 2026. This represents a decrease of 57.1% from the same quarter a year earlier. Against the prior quarter it is down 57.1%.
Impact BioMedical, Inc.'s EBITDA was -$418K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Impact BioMedical, Inc. reported a net loss of $699K in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Impact BioMedical, Inc. held $10K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Impact BioMedical, Inc.'s gross margin was 66.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 123.8 percentage points from the same quarter a year earlier.
Impact BioMedical, Inc.'s quarterly ROE was -6.5% in Q2 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is up 13.5 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Impact BioMedical, Inc. invested $76K in research and development in Q2 2026. This represents an increase of 1.3% from the same quarter a year earlier. Against the prior quarter it is up 65.2%.
Not reported for Q2 2026.
Not reported for Q2 2026.
IBO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3K-57.1% | $7K | N/A | $18K | $7K | N/A | N/A | N/A |
| Cost of Revenue | $1K-90.9% | N/A | N/A | $1K | $11K | N/A | N/A | N/A |
| Gross Profit | $2Kn/m | N/A | N/A | $17K | -$4K | N/A | N/A | N/A |
| R&D Expenses | $76K+1.3% | $46K-55.3% | $110K | $52K-36.6% | $75K-38.0% | $103K-43.7% | N/A | $82K-77.0% |
| SG&A Expenses | $167K-32.1% | $1.6M+553.2% | $118K | $261K+97.7% | $246K+69.7% | $248K+67.6% | N/A | $132K+30.7% |
| Operating Income | -$702Kn/m | -$2.3Mn/m | -$1.2Mn/m | -$948Kn/m | -$1.2Mn/m | -$1.0Mn/m | -$26.2Mn/m | -$1.1Mn/m |
| EBITDA | -$418Kn/m | -$2.0Mn/m | N/A | -$660Kn/m | -$865Kn/m | -$727Kn/m | N/A | -$846Kn/m |
| Interest Expense | N/A | N/A | N/A | $262K-14.1% | $260K-0.4% | $271K+17.8% | N/A | $305K+199.0% |
| Net Income | -$699Kn/m | -$2.3Mn/m | $5.2M | -$1.5M-134.6% | -$14.3Mn/m | -$1.3Mn/m | N/A | $4.2Mn/m |
| EPS (Basic) | -$0.01 | -$0.02 | N/A | -$0.12 | -$1.18n/m | -$0.11n/m | -$2.53n/m | $0.37n/m |
| EPS (Diluted) | -$0.01 | -$0.02 | N/A | -$0.12 | -$1.18n/m | -$0.11n/m | -$2.33n/m | $0.06n/m |
Not reported in any period shown, so not listed: Income Tax, Diluted Shares (Avg).
IBO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $16.7M-12.1% | $17.1M-14.8% | $17.4M-14.2% | $18.2M-61.0% | $19.1M-56.8% | $20.1M-54.8% | $20.3M-54.5% | $46.7M+3.6% |
| Current Assets | $320K-78.4% | $377K-82.7% | $411K-83.2% | $917K-71.1% | $1.5M+382.4% | $2.2M+551.6% | $2.4M+637.3% | $3.2M+533.7% |
| Cash & Equivalents | $10K-98.4% | $20K-98.5% | $3K-99.8% | $12K-99.6% | $624K+31100.0% | $1.3M+65800.0% | $2.0M+199800.0% | $2.7M+1227.4% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $62K-87.2% | $63K-87.1% | $63K | $485K | $486K | $489K | N/A | N/A |
| Accounts Receivable | N/A | N/A | $5K | $15K | N/A | $4K-96.9% | N/A | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $25.1M-45.9% |
| Total Liabilities | $2.7M-89.7% | $2.4M-82.1% | $1.9M-85.8% | $27.1M+119.2% | $26.4M+27.5% | $13.2M-34.1% | $13.1M-20.3% | $12.3M-20.4% |
| Current Liabilities | $2.0M-91.2% | $1.7M-83.1% | $1.2M-88.1% | $23.8M+1990.8% | $23.2M+59.8% | $10.0M-28.0% | $9.8M-25.5% | $1.1M-90.7% |
| Non-Current Liabilities | $688K-78.9% | $688K-78.9% | $688K-78.9% | $3.3M-70.8% | $3.3M-47.7% | $3.3M-47.6% | $3.3M+1.0% | $11.2M+246.4% |
| Total Equity | $10.8Mn/m | $11.5M+198.3% | $12.3M+189.1% | -$11.8M-137.7% | -$10.3M-144.2% | $3.8M-84.2% | $4.3M-83.1% | $31.3M+18.2% |
| Retained Earnings | -$52.5Mn/m | -$51.8Mn/m | -$49.5Mn/m | -$54.8Mn/m | -$53.3Mn/m | -$38.9Mn/m | -$37.7Mn/m | -$10.6Mn/m |
Not reported in any period shown, so not listed: Long-Term Debt.
IBO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $470Kn/m | -$464Kn/m | $99Kn/m | -$613Kn/m | -$694Kn/m | -$682Kn/m | -$986Kn/m | -$1.0Mn/m |
| Depreciation & Amortization | $284K-1.4% | $285K+0.7% | $286K+2.5% | $288K+2.5% | $288K+3.2% | $283K+1.1% | $279K-0.4% | $281K+0.4% |
| Stock-Based Compensation | $0-100.0% | $1.4M+71900.0% | N/A | N/A | $2K | $2K | N/A | N/A |
| Investing Cash Flow | $2Kn/m | -$1K-200.0% | $1Kn/m | $1K0.0% | $0 | $1K | $0-100.0% | $1Kn/m |
| Financing Cash Flow | N/A | $482K | N/A | N/A | N/A | N/A | $317K+36.6% | $3.7M+321.4% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
IBO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.7%+123.8pp | N/A | N/A | 94.4% | -57.1% | N/A | N/A | N/A |
| Operating Margin | -23400.0% | -32700.0% | N/A | -5266.7% | -16471.4% | N/A | N/A | N/A |
| Net Margin | -23300.0% | -32671.4% | N/A | -8166.7% | -204942.9% | N/A | N/A | N/A |
| Return on Equity | -6.5% | -20.0%+13.0pp | 42.6% | N/A | N/A | -33.0%-29.0pp | N/A | 13.6%+18.0pp |
| Return on Assets | -4.2%+71.1pp | -13.4%-7.1pp | 30.1% | -8.1%-17.2pp | -75.3%-73.3pp | -6.3%-4.2pp | N/A | 9.1%+11.7pp |
| Current Ratio | 0.16+0.1x | 0.220.0x | 0.35+0.1x | 0.04-2.8x | 0.060.0x | 0.22+0.2x | 0.25+0.2x | 2.79+2.7x |
| Liabilities-to-Equity | 0.25 | 0.21-3.2x | 0.15-2.9x | N/A | N/A | 3.45+2.6x | 3.06+2.4x | 0.39-0.2x |
| Asset Turnover | 0.000.0x | 0.00 | N/A | 0.00 | 0.00 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.35), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Impact BioMedical, Inc. IBO | FY2025 | $32K | -$11.8M | N/A | $34.3M | — |
| Pelthos Therapeutics Inc. PTHS | FY2025 | $16.8M | -$43.3M | N/A | $44.1M | 25/100 |
| Lite Strategy, Inc. LITS | FY2026 | $267K | -$71.2M | N/A | $29.4M | — |
| Veru Inc. VERU | FY2025 | N/A | -$22.7M | N/A | $36.8M | — |
| NanoViricides Inc. NNVC | FY2026 | $0 | -$8.2M | N/A | $34.5M | — |
| Aldeyra Therapeutics, Inc. ALDX | FY2025 | N/A | -$33.8M | N/A | $35.2M | — |
Where Impact BioMedical, Inc. Ranks
Frequently Asked Questions
Impact BioMedical, Inc. (IBO) reported $32K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
No, Impact BioMedical, Inc. (IBO) reported a net loss of $11.8M in fiscal year 2025.
Impact BioMedical, Inc. (IBO) had EBITDA of -$3.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Impact BioMedical, Inc. (IBO) has a return on equity of -96.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Impact BioMedical, Inc. (IBO) recorded an outflow of $1.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Impact BioMedical, Inc. (IBO) had $17.4M in total assets as of fiscal year 2025, including both current and long-term assets.
Impact BioMedical, Inc. (IBO) invested $340K in research and development during fiscal year 2025.
Impact BioMedical, Inc. (IBO) had a current ratio of 0.35 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Impact BioMedical, Inc. (IBO) had a liabilities-to-equity ratio of 0.15 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Impact BioMedical, Inc. (IBO) had a return on assets of -68.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Impact BioMedical, Inc. (IBO) trades at 43.4x earnings, its market capitalization divided by $789K net income, trailing 12 months to June 30, 2026. The market capitalization is $34.3M as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Impact BioMedical, Inc. (IBO) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $32K revenue, FY2025). The market capitalization is $34.3M as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Impact BioMedical, Inc. (IBO) held $3K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.9M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Impact BioMedical, Inc. (IBO) has an Altman Z-Score of 6.27, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Impact BioMedical, Inc. (IBO) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Impact BioMedical, Inc. (IBO) reported a net loss of $11.8M while operations used $1.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Impact BioMedical, Inc. (IBO) reported an operating loss of $4.3M against $793K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.